miRNA Sequencing and Assay Market Growth Boosted by Advances in Genomic Research: Persistence Market Research

The miRNA sequencing and assay market has emerged as a critical segment in the broader genomics industry, providing innovative tools to explore gene regulation and biomarker discovery. As the demand for personalized medicine, non-coding RNA research, and high-throughput sequencing grows, the market has shown consistent and accelerated growth. According to a comprehensive study by Persistence Market Research, global miRNA sequencing and assay sales reached US$ 267.7 Mn in 2022, and are projected to grow to US$ 1.4 Bn by 2032, expanding at a CAGR of 18.1% during the forecast period.

North America stands as the leading geographical region, driven by the presence of major market players like Illumina, Thermo Fisher Scientific, and PerkinElmer, along with heavy R&D investments and robust healthcare infrastructure. Among technology segments, Sequencing by Synthesis (SBS) dominates due to its high accuracy and efficiency in miRNA detection. This technique is especially valuable for single-base resolution studies and high-throughput applications, ensuring its sustained relevance through 2032.

Get a Sample Copy of Research Report (Use Corporate Mail id for Quick Response): https://www.persistencemarketresearch.com/samples/33228

Key Highlights from the Report

• The global miRNA sequencing and assay market is projected to grow at 18.1% CAGR from 2022 to 2032.
• Sequencing by Synthesis is the leading technology, growing at a CAGR of 20.8%.
• North America holds the highest market share due to technological innovation and key players.
• Asia-Pacific is projected to be the fastest-growing region, supported by bioinformatics education and infrastructure.
• Product segment is expected to be the top revenue contributor among component types.
• Covid-19 research triggered increased interest in miRNA-host interactions, boosting market relevance.

Market Segmentation

The miRNA sequencing and assay market is segmented into products, services, technology, and end-users. The product segment, which includes library preparation kits, reagents, consumables, and sequencing platforms, is expected to grow at the fastest pace. This growth is supported by continuous innovation by companies such as Illumina, which provides comprehensive tools for miRNA sequencing workflows. New algorithms like BrumiR, designed for direct miRNA discovery from sRNA-seq data, also enhance product efficiency and performance.

End-user segmentation reveals that academic and research institutes, followed by pharmaceutical and biotechnology companies, are the primary adopters. Increased academic research in RNA biology and collaborations with biotech firms to discover miRNA biomarkers are key drivers. Pharmaceutical companies are integrating miRNA sequencing for drug discovery, toxicity testing, and therapeutic development, further expanding the commercial use of these assays.

Read Detailed Analysis: https://www.persistencemarketresearch.com/market-research/mirna-sequencing-and-assay-market.asp

Regional Insights

North America remains the dominant market, thanks to strong government support, advanced infrastructure, and a high concentration of biotech firms. Companies in the U.S. are significantly investing in sequencing R&D. For example, Illumina spent over US$ 680 million in R&D in 2020 alone, showcasing its dedication to maintaining technological leadership.

Meanwhile, the Asia-Pacific region, including countries like Japan, South Korea, and China, is forecasted to witness the fastest growth. Initiatives such as APBioNet are supporting researcher training and international collaboration, significantly boosting the adoption of miRNA sequencing platforms and techniques in the region.

Market Drivers

The market is propelled by the rising prevalence of neurological, cardiovascular, and infectious diseases, which require deeper molecular-level analysis. miRNAs are increasingly recognized as critical biomarkers for disease detection, prognosis, and therapeutic targeting. Technological advancements in next-generation sequencing (NGS), reduction in sequencing costs, and increased accessibility to bioinformatics tools are also bolstering adoption.

Moreover, personalized medicine continues to push demand for individualized diagnostic and therapeutic solutions, in which miRNA profiling plays a key role. The identification of disease-specific miRNAs offers a pathway to develop precise therapies and companion diagnostics, creating numerous opportunities for commercial and academic research.

Market Restraints

Despite strong growth, the market faces several challenges. One significant restraint is the high cost of sequencing equipment and consumables, making adoption difficult for small- to mid-sized research institutions. Moreover, technical complexities in miRNA data analysis, particularly the differentiation between isoforms like isomiRs, necessitate advanced bioinformatics expertise, which may be lacking in some regions.

Additionally, data interpretation and reproducibility issues can affect assay reliability, especially when dealing with low-expression miRNAs or degraded samples. Regulatory uncertainties surrounding miRNA-based diagnostics also pose hurdles for companies seeking product approval and commercialization.

Market Opportunities

As research into non-coding RNAs deepens, the opportunity for therapeutic and diagnostic applications of miRNA expands significantly. Emerging technologies like liquid biopsy, which rely on miRNA expression in bodily fluids, offer non-invasive solutions for early cancer detection and monitoring, creating new commercial avenues.

The increasing use of AI and machine learning in bioinformatics is another major opportunity. These tools help identify novel miRNAs, understand gene regulation networks, and predict disease associations, all of which enhance the clinical value of sequencing data. Partnerships between tech and biotech firms can further drive innovation in this space.

Request for Customization of the Research Report: https://www.persistencemarketresearch.com/request-customization/33228

Reasons to Buy the Report

• Comprehensive market analysis covering 10-year forecasts from 2022 to 2032.
• Insights into emerging technologies like BrumiR and SBS, which are revolutionizing the market.
• In-depth regional breakdowns highlighting growth hotspots and investment opportunities.
• Evaluation of leading players and competitive strategies to navigate the market landscape.
• Detailed segmentation by component, technology, and end-user for targeted investment planning.

Frequently Asked Questions (FAQs)

• How big is the miRNA Sequencing and Assay Market in 2025?
• Who are the key players in the global miRNA sequencing and assay market?
• What is the projected growth rate of the miRNA sequencing and assay market?
• What is the market forecast for miRNA sequencing and assay through 2032?
• Which region is estimated to dominate the industry through the forecast period?

Company Insights

Key players operating in the miRNA sequencing and assay market include:

• Thermo Fisher Scientific
• Illumina
• QIAGEN
• PerkinElmer
• Abcam plc
• New England Biolabs
• Takara Bio Inc.
• Lexogen GmbH
• Norgen Biotek Corp
• Maravai LifeSciences
• HTG Molecular Diagnostics
• Meridian Bioscience, Inc.
• System Biosciences, LLC

Recent Developments

• In January 2022, a groundbreaking study demonstrated absolute quantification of circulating miRNA biomarkers using the miND assay, opening up new applications for disease diagnosis and prognosis.

• In June 2020, Lexogen GmbH launched the TraPR Small RNA Isolation Kit, a next-gen product offering highly efficient purification of functional small RNAs, enabling high-throughput sequencing and analysis.

Conclusion

The miRNA sequencing and assay market is on a strong growth trajectory, driven by expanding applications in precision medicine, cancer diagnostics, and molecular biology research. With a projected CAGR of 18.1% and a market size expected to exceed US$ 1.4 Bn by 2032, the landscape presents a wealth of opportunities for both established players and emerging innovators. Strategic investments in R&D, bioinformatics capabilities, and global partnerships will be crucial to unlocking the full potential of miRNA technologies.

As tracked by Persistence Market Research, the continued push toward personalized medicine, combined with technological advancements and regulatory maturity, will define the next chapter for this transformative market.

Read More Related Reports:

Hospital Treated Gram Negative Infections Market https://www.persistencemarketresearch.com/market-research/hospital-treated-gram-negative-infections-market.asp
High Content Screening Market https://www.persistencemarketresearch.com/market-research/high-content-screening-market.asp
Wheelchair And Components Market https://www.persistencemarketresearch.com/market-research/wheelchair-and-components-market.asp
North America Wound Debridement Products Market https://www.persistencemarketresearch.com/market-research/north-america-wound-debridement-products-market.asp
Dysphagia Management Market https://www.persistencemarketresearch.com/market-research/dysphagia-management-market.asp

Contact Us:

Persistence Market Research
G04 Golden Mile House, Clayponds Lane
Brentford, London, TW8 0GU UK
USA Phone: +1 646-878-6329
UK Phone: +44 203-837-5656
Email: sales@persistencemarketresearch.com
Web: https://www.persistencemarketresearch.com

About Persistence Market Research:

At Persistence Market Research, we specialize in creating research studies that serve as strategic tools for driving business growth. Established as a proprietary firm in 2012, we have evolved into a registered company in England and Wales in 2023 under the name Persistence Research & Consultancy Services Ltd. With a solid foundation, we have completed over 3600 custom and syndicate market research projects, and delivered more than 2700 projects for other leading market research companies' clients.

Our approach combines traditional market research methods with modern tools to offer comprehensive research solutions. With a decade of experience, we pride ourselves on deriving actionable insights from data to help businesses stay ahead of the competition. Our client base spans multinational corporations, leading consulting firms, investment funds, and government departments. A significant portion of our sales comes from repeat clients, a testament to the value and trust we've built over the years.

This release was published on openPR.